You are here: Industry Insights > Incyte

News List

Incyte and MorphoSys Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Ly firstwordpharma
August 27, 2021
Incyte (Nasdaq:INCY) and MorphoSys AG (FSE:MOR; NASDAQ:MOR) today announced that the European Commission (EC) has granted conditional marketing authorization for Minjuvi® (tafasitamab) in combination with lenalidomide, followed by Minjuvi monotherapy.
Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation worldpharmanews
August 04, 2021
Eli Lilly and Company and Incyte announced results from an additional cohort of 101 adult patients from the COV-BARRIER trial. In this sub-study, patients with COVID-19 on mechanical ventilation or extracorporeal membrane oxygenation (ECMO) who ...
Lilly-Incyte’s baricitinib lowers mortality in Phase III Covid-19 trial pharmaceutical-technology
August 04, 2021
Eli Lilly and Incyte have reported new data from Phase III COV-BARRIER sub-study, where baricitinib lowered mortality risk in Covid-19 patients receiving mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
FDA expands EUA for Lilly-Incyte’s baricitinib as Covid-19 monotherapy pharmaceutical-technology
July 30, 2021
The US Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for Eli Lilly and Incyte’s drug, baricitinib, for Covid-19 treatment with or without remdesivir.
Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) drugs
July 30, 2021
Incyte Corporation (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab.
NICE recommends Incyte’s Pemazyre for rare bile duct cancer pharmatimes
July 23, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for Incyte Biosciences UK’s Pemazyre for the treatment of the rare bile duct cancer cholangiocarcinoma (CCA).
Topical JAK inhibitors becoming a major force in atopic dermatitis space: GlobalData expresspharma
July 05, 2021
An increasing number of JAK agents are filling the early and late-stage pipeline. Of the 98 pipeline agents, eight are JAKs – with six of these being topical formulations.
Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) firstwordpharma
June 25, 2021
ncyte (Nasdaq:INCY) today announced the outcome of a meeting of the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA), which reviewed the Biologics License Application for retifanlimab, an intravenous PD-1 inhibitor.
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Taiwan, China Market for the Treatment of Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with a F prnasia
June 22, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases announced that the Taiwan, China market has
Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis drugs
June 21, 2021
Incyte Corporation (Nasdaq:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for ruxolitinib cream for the treatment of atopic dermatitis (AD).

Previous page 1 2 3 4 5 Next page